Incidence of ovarian, peritoneal, and fallopian tube carcinomas in the United States, 1995-2004

Cancer Epidemiology Biomarkers and Prevention

Volumn 18, Issue 1, 2009, Pages 132-139

  Goodman, Marc T ^a   Shvetsov, Yurii B ^a  

^a UNIVERSITY OF HAWAII CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CANCER INCIDENCE; CANCER STAGING; CLINICAL FEATURE; CONTROLLED STUDY; DEMOGRAPHY; ETHNIC DIFFERENCE; FEMALE; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; OVARY CARCINOMA; PERITONEUM CANCER; PRIORITY JOURNAL; RACE DIFFERENCE; UNITED STATES; UTERINE TUBE CARCINOMA;

ADOLESCENT; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; CHILD; FALLOPIAN TUBE NEOPLASMS; FEMALE; HUMANS; INCIDENCE; MIDDLE AGED; NEOPLASM STAGING; OVARIAN NEOPLASMS; PERITONEAL NEOPLASMS; REGISTRIES; SEER PROGRAM; UNITED STATES;

EID: 58349096907     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-08-0771     Document Type: Article

References (39)

1. Roffers SD, Wu XC, Johnson CH, Correa CN. Incidence of extraovarian primary cancers in the United States, 1992-1997. Cancer 2003;97:2643-7.
2. Jarboe EA, Folkins AK, Drapkin R, Ince TA, Agoston ES, Crum CP. Tubal and ovarian pathways to pelvic epithelial cancer: a pathological perspective. Histopathology 2008;53:127-38.
3. Halperin R, Zehavi S, Langer R, Hadas E, Bukovsky I, Schneider D. Primary peritoneal serous papillary carcinoma: a new epidemiologic trend? A matched-case comparison with ovarian serous papillary cancer. Int J Gynecol Cancer 2001;11:403-8.
4. Eltabbakh GH, Piver MS, Natarajan N, Metlin CJ. Epidemiologic differences between women with extraovarian primary peritoneal carcinoma and women with epithelial ovarian cancer. Obstet Gynecol 1998;1:254-9.
5. Chou CS, Menzin AW, Leonard DGB, Rubin SC, Wheeler E. Primary peritoneal carcinoma: a review of the literature. Obstet Gynecol Surv 1999;54:323-35.
6. Barda G, Menczer J, Chetrit A, et al. Comparison between primary peritoneal and epithelial ovarian carcinoma: a population-based study. Am J Obstet Gynecol 2004;190:1039-45.
7. Gadducci A, Landoni F, Sartori E, et al. Analysis of treatment failures and survival of patients with fallopian tube carcinoma: a cooperation task force (CTF) study. Gynecol Oncol 2001;81:150-9.
8. Goodman MT, Howe HL. Descriptive epidemiology of ovarian cancer in the United States, 1992-1997. Cancer 2003;97:2615-30.
9. Zeig-Owens R, Knowlton R, Gershman ST, Howe HL. CINA highlights of cancer incidence and mortality in the United States and Canada, 2000-2004. Springfield (IL): North American Association of Central Cancer Registries, Inc. 2007.
10. NAACCR Expert Panel in Hispanic Identification. Report of the NAACCR Expert Panel on Hispanic Identification 2003. Springfield (IL): North American Association of Central Cancer Registries; 2003. Available from: http://www.naaccr.org.
11. U.S. Census Bureau. United States Census 2000 [accessed 2008 July 31]. Available from: http://www.census.gov/population/www/.
12. Fritz A, Percy C, Jack A, et al. International Classification of Disease for Oncology. 3rd ed. Geneva: World Health Organization; 2000.
13. Shambaugh EM, Weiss MA, editors. Summary staging guide (SSS1977). Cancer Surveillance Epidemiology and End Results Reporting, SEER Program, April 1977. NIH Publication No. 01-2313. Bethesda (MD): National Cancer Institute; 2001.
14. Young JL, Jr., Roffers SD, Reis LAG, Fritz AG, Hurlbut AA, editors. SEER summary staging manual - 2000 codes and coding instructions (SSS2000). NIH Publication No. 01-4969. Bethesda (MD): National Cancer Institute; 2001.
15. Phillips JL, editor. Summary stage: data effects of the changes in 2000. Springfield (IL): North American Association of Central Cancer Registries; 2003. Available from: http://www.naaccr.org.
16. Surveillance Research Program, National Cancer Institute SEER*Stat software version 6.4.4. Bethesda (MD): National Cancer Institute. Available from: http://www.SEER.cancer.gov/SEERstat.
17. Fay MP, Feuer EJ. Confidence intervals for directly standardized rates: a method based on the γ distribution. Stat Med 1997;16:791-801.
18. Fay MP. Approximate confidence intervals for rate ratios from directly standardized rates with sparse data. Commun Stat Theor Meth 1999;28:2141-60.
19. Fay MP, Tiwari RC, Feuer EJ, Zou Z. Estimating average annual percent change for disease rates without assuming constant change. Biometrics 2006;62:847-54.
20. Agresti A. Categorical data analysis. 2nd ed. Hoboken (NJ): Wiley; 2002.
21. Goodman MT, Howe HL, Tung KH, et al. Incidence of ovarian cancer by race and ethnicity in the United States, 1992-1997. Cancer 2003;97:2676-85.
22. Stewart SL, Wike JM, Foster SI, Michaud F. The incidence of primary fallopian tube cancer in the United States. Gynecol Oncol 2007;107:392-7.
23. Riska A, Leminen A, Pukkala E. Sociodemographic determinants of incidence of primary fallopian tube carcinoma, Finland 1953-97. Int J Cancer 2003;104:643-5.
24. Pfeiffer P, Mogensen H, Amtrup F, Honore E. Primary carcinoma of the fallopian tube. A retrospective study of patients reported to the Danish cancer registry in a five-year period. Acta Oncol 1989;28:7-11.
25. Pectasides D, Pectasides E, Economopoulos T. Fallopian tube carcinoma: a review. Oncologist 2006;11:902-12.
26. Riska A, Sund R, Pukkala E, Gissler M, Leminen A. Parity, tubal sterilization, hysterectomy and risk of primary fallopian tube carcinoma in Finland, 1975-2004. Int J Cancer 2007;120:1351-4.
27. Inal MM, Hanhan M, PIlanci B, Tinar S. Fallopian tube malignancies: experience of Social Security Agency Aegean Maternity Hospital. Int J Gynecol Cancer 2004;14:595-9.
28. Zweemer RP, van Diest PJ, Verheijen RH, et al. Molecular evidence linking primary cancer of the fallopian tube to BRCA1 germline mutations. Gynecol Oncol 2000;76:45-50.
29. Aziz S, Kuperstein G, Rosen B, et al. A genetic epidemiological study of carcinoma of the fallopian tube. Gynecol Oncol 2001;80:341-5.
30. Haber D. Prophylactic oophorectomy to reduce the risk of ovarian and breast cancer in carriers of BRCA mutations. N Engl J Med 2002;346:1660-2.
31. Swerdlow M. Mesothelioma of the pelvic peritoneum resembling papillary cystadenocarcinoma of the ovary; case report. Am J Obstet Gynecol 1959;77:197-200.
32. Menczer J, Chetrit A, Barda G, et al. Frequency of BRCA mutations in primary peritoneal carcinoma in Israeli Jewish women. Gynecol Oncol 2003;88:58-61.
33. Bandera CA, Schorge JO, Muto MG, Berkowitz RS, Rubin SC, Mok SC. BRCA1 gene mutations in women with papillary serous carcinoma of the peritoneum. Obstet Gynecol 1998;92:596-600.
34. Hall HI, Tung KH, Hotes J, Logan P. Regional variations in ovarian cancer incidence in the United States, 1992-1997. Cancer 2003;97:2701-6.
35. Kurman RJ, Shih IeM. Pathogenesis of ovarian cancer: lessons from morphology and molecular biology and their clinical implications. Int J Gynecol Pathol 2008;27:151-60.
36. Chen LM, Yamada SD, Fu YS, Baldwin RL, Karlan BY. Molecular similarities between primary peritoneal and primary ovarian carcinomas. Int J Gynecol Cancer 2003;13:749-55.
37. O'Malley C, Hu KU, West DW. North American Association of Central Cancer Registries: race and ethnicity identifier assessment project, 2002. Available from: http://www.naaccr.org.
38. Kolonel LN, Goodman MT. Racial variation in cancer: fact or artifact? J Natl Cancer Inst 1992;84:916-7.
39. Clegg LX, Reichman ME, Hankey BF, et al. Quality of race, Hispanic ethnicity, and immigrant status in population-based cancer registry data: implications for health disparity studies. Cancer Causes Control 2007;18:177-87.